Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 943-728-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Remarks:
- DRF for OECD 408 test
- Adequacy of study:
- supporting study
- Study period:
- 01.12.2021 - Pending final QA report issue
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: DRF for OECD 408 study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
Materials and methods
Test guideline
- Qualifier:
- no guideline required
- GLP compliance:
- no
- Remarks:
- DRF study so no GLP required
Test material
- Reference substance name:
- Reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde
- EC Number:
- 943-728-2
- Molecular formula:
- C9H14O
- IUPAC Name:
- Reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source (i.e. manufacturer or supplier) and lot/batch number of test material: Sponsor; SHT036
- Purity, including information on contaminants, isomers, etc.: 99.48% (sum of isomers)
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Store at laboratory conditions, protected from heat and light
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Wistar Crl
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River SPF breeding, supplied via VELAZ s.r.o.,
Czech Republic, RČH CZ 11760500
- Age at study initiation: 8 weeks on arrival
- Diet: Maintenance pelleted diet for rats and mice - Altromin for rats/mice, Manufacturer: Altromin Spezialfutter GmbH & Co. KG, Germany
- Water: drinking water ad libitum, quality corresponding to the Regulation No. 252/2004 of Czech Coll. of Law
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 30-70 %
- Photoperiod (hrs dark / hrs light): 12 hours light, 12 hours dark
- Air changes: 15 per hour
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The concentrations of suspension at all dose levels were adjusted to ensure the administration of 1 mL per 100 g of body weight. For each dose level concentration, the suspension was prepared separately. The administration of the test item to animals was performed during one hour after preparation of application form. The stirring of suspension continued during administration.
VEHICLE
The test item was administered to the stomach by gavage as a suspension in an olive oil (olive oil (batch number: 20D09-T10; CAS number: 8001-25-0)).The vehicle control group was administered olive oil in the same volume. - Analytical verification of doses or concentrations:
- no
- Remarks:
- Stability and homogeneity were confirmed in a separate analytical study (refer to Key study record)
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 62.5 mg/kg bw/day (nominal)
- Dose / conc.:
- 250 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 6 males and 6 females per dose
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
Control of the health condition was performed once a day during animal handling before the application of the test item.
DETAILED CLINICAL OBSERVATIONS: Yes
During the whole study in scheduled intervals the clinical observation were made in order to record possible clinical effect of the test item after application and all changes in behaviour of animals. Animals were observed in natural conditions in their cages.
BODY WEIGHT: Yes
The body weight of animals was recorded on automatic balances with group average computing module.
First weighing was performed before the first application and then weekly. Weight increment will be computed as an average per group per week (in grams).
HAEMATOLOGY: Yes
Before necropsy of animals the blood samples were collected from the orbital plexus by glass micropipette under the light diethyl ether narcosis into the PVC test tubes containing anticoagulation systems. Basic blood parameters (total erythrocyte count, total leucocyte count, mean corpuscule volume, haematocrit, haemoglobin concentration, total platelet count) will be determined on haematology analyser. - Sacrifice and pathology:
- The animals (on the 28th day of study) was humanely killed under ether anaesthesia by breaking the cervical spinal cord. During the necropsy a revision of the external surface of the body, of all orifices and the cranial, thoracic and abdominal cavities were carried out. All macroscopic changes found were recorded in protocols.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- No changes of animal health status or clinical symptoms of intoxication were observed in animals at the dose levels 62.5 and 250 mg/kg bw/day and in animals of the control group. In males dosed at 1000 mg/kg bw/day, decreased response to stimuli (auditory, visual and proprioceptive) was observed from the 4th to 8th day of the application period. In male No. 34 piloerection and apathy were also observed on the 9th and 10th days of the application period. No changes of animal health status or clinical symptoms of intoxication from the 9th day to the end of study in males at the dose level 1000 mg/kg bw/day were observed.
No changes of animal health status or clinical symptoms of intoxication were observed in animals at the dose levels 62.5 and 250 mg/kg bw/day and in animals of the control group. In females dosed at 1000 mg/kg bw/day, decreased response to stimuli (auditory, visual and proprioceptive) was observed from the 4th to 8th day of the application period. No changes of animal health status or clinical symptoms of intoxication from the 9th day to the end of study in females at the dose level 1000 mg/kg bw/day were observed. - Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- During the DRFE one male rat (at the dose level 1000 mg/kg bw/day) died on the 10th day of the study. The cause of death was not identified during necropsy.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Upon necropsy, the body weights of all treated males were lower compared to the control group. The decrease in body weight was marked in the first week of application but then recovered throughout the remaining weeks of the study.
Upon necropsy, the body weights of all treated females were slightly higher compared to the control group. Body weight of females at the dose level 1000 mg/kg bw/day was slightly increased every week of the study, compared to the 62.5 and 250 mg/kg bw/day dose groups.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The values of total leucocyte count, total erythrocyte count and haematocrite were slightly decreased in males at the dose level 1000 mg/kg bw/day, in comparison with the control group.
Other parameters did not show differences among dose levels. - Clinical biochemistry findings:
- not examined
- Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No macroscopic changes were observed during necropsy of treated males and control males. The cause of death of male rate No. 34 (1000 mg/kg bw/day, Day 10) was not identified during necropsy.
No macroscopic changes were observed during necropsy of treated females and control females. - Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
Effect levels
- Dose descriptor:
- other: No NOAEL; doses selected for main study
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Refer to Tables 3-5 attached.
Applicant's summary and conclusion
- Conclusions:
- On the basis of the results given above the following dose levels – 62.5, 250 and 1000 mg/kg bw/day were proposed for the main Repeated Dose 90-day Oral Gavage Toxicity Study.
- Executive summary:
In a dose range finding study (no guideline), for a repeated dose 90 day oral toxicity study (OECD 408/GLP), the test item (99.48% (sum of isomers)) was administered to
Wistar Crl rats (6/sex/dose) by gavage in olive oil at dose levels of 0, 62.5, 250 and 1000 mg/kg bw/day for 28 days.
One male at the high dose (1000 mg/kg bw/day) died on Day 10. In all male and female animals at the high dose (1000 mg/kg bw/day), decreased response to stimuli (auditory, visual and proprioceptive) was observed from the 4th to 8th day of the application period. Clinical observation of animals at the mid dose level (250 mg/kg bw/day) and low dose level (62.5 mg/kg bw/day) did not detect any impact of the test item on the health condition of the animals.Upon necropsy, the body weights of all treated males were lower compared to the control group. The decrease in body weight was marked in the first week of application but then recovered throughout the remaining weeks of the study. Upon necropsy, the body weights of all treated females were slightly higher compared to the control group. Body weight of females at the dose level 1000 mg/kg bw/day was slightly increased every week of the study, compared to the 62.5 and 250 mg/kg bw/day dose groups.
Haematological examination showed slightly decreased values of total leucocyte count, total erythrocyte count and haematocrit in males at the high dose (1000 mg/kg bw/day) in comparison with the control group. Other examined parameters in all other males and females did not show differences among dose levels.No macroscopic changes were observed during necropsy of treated male and female animals. The cause of death of one male rat (1000 mg/kg bw/day, Day 10) was not identified during necropsy.
On the basis of the results given above the following dose levels – 62.5, 250 and 1000 mg/kg bw/day were proposed for the main Repeated Dose 90-day Oral Gavage Toxicity Study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
